Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2016 to Q2 2023

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
SYRS on Nasdaq
Shares outstanding
27,995,500
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Invus Global Management, LLC 3.8% $776,595 1,063,829 Invus Public Equities, L.P. 31 Dec 2024

Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2023 Q2 0 $0 -$585 0
2023 Q1 219 $585 $2.67 1
2022 Q4 219 $786 -$5,677,000 $3.59 1
2022 Q3 881,719 $5,679,000 -$38,920,523 $6.44 3
2022 Q2 35,563,928 $34,226,317 -$9,550,880 $0.96 58
2022 Q1 44,600,309 $53,054,739 -$16,229,688 $1.19 86
2021 Q4 51,167,771 $165,935,422 +$2,424,541 $3.26 84
2021 Q3 47,185,070 $209,928,186 -$4,801,116 $4.47 92
2021 Q2 47,939,973 $259,937,712 -$108,395,908 $5.45 95
2021 Q1 60,879,549 $453,765,087 +$51,303,227 $7.48 99
2020 Q4 53,645,472 $580,176,544 +$89,474,242 $10.85 99
2020 Q3 46,027,616 $405,893,308 +$16,189,114 $8.84 91
2020 Q2 39,975,459 $425,248,905 +$6,981,050 $10.66 77
2020 Q1 44,878,307 $265,481,374 +$15,181,069 $5.93 63
2019 Q4 42,159,417 $290,644,730 -$8,983,413 $6.91 70
2019 Q3 43,076,602 $446,224,216 +$88,973,322 $10.38 61
2019 Q2 31,644,913 $291,721,875 +$102,579,332 $9.26 66
2019 Q1 20,623,242 $188,494,058 +$16,131,561 $9.14 63
2018 Q4 22,234,612 $123,844,000 +$995,029 $5.57 67
2018 Q3 17,416,778 $207,439,026 +$2,479,368 $11.91 73
2018 Q2 17,226,749 $175,885,142 +$16,540,742 $10.21 73
2018 Q1 18,506,513 $240,212,598 +$38,686,687 $12.98 54
2017 Q4 15,877,766 $154,493,194 +$4,671,125 $9.73 68
2017 Q3 12,031,237 $177,159,772 +$16,405,535 $14.72 66
2017 Q2 10,799,619 $173,764,545 +$43,612,075 $16.09 45
2017 Q1 12,887,128 $205,289,593 +$2,132,231 $15.93 42
2016 Q4 12,922,246 $157,133,459 +$1,761,438 $12.16 40
2016 Q3 12,757,094 $176,293,302 +$3,959,949 $13.87 34
2016 Q2 7,667,574 $119,948,000 +$119,948,000 $18.15 11